Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study

2013 ◽  
Vol 20 (6) ◽  
pp. 669-674 ◽  
Author(s):  
Andreas Lossius ◽  
Trond Riise ◽  
Maura Pugliatti ◽  
Kjetil Bjørnevik ◽  
Ilaria Casetta ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Solar Radiation ◽  
Infectious Mononucleosis ◽  
Similar Degree ◽  
Barr Virus ◽  
Vitamin D Levels ◽  
Epstein Barr ◽  
Control Study ◽  
Subsequent Risk

Background: Seasonal fluctuations in solar radiation and vitamin D levels could modulate the immune response against Epstein-Barr virus (EBV) infection and influence the subsequent risk of multiple sclerosis (MS). Methods: Altogether 1660 MS patients and 3050 controls from Norway and Italy participating in the multinational case-control study of Environmental Factors In Multiple Sclerosis (EnvIMS) reported season of past infectious mononucleosis (IM). Results: IM was generally reported more frequently in Norway ( p=0.002), but was associated with MS to a similar degree in Norway (odds ratio (OR) 2.12, 95% confidence interval (CI) 1.64–2.73) and Italy (OR 1.72, 95% CI 1.17–2.52). For all participants, there was a higher reported frequency of IM during spring compared to fall ( p<0.0005). Stratified by season of IM, the ORs for MS were 1.58 in spring (95% CI 1.08–2.31), 2.26 in summer (95% CI 1.46–3.51), 2.86 in fall (95% CI 1.69–4.85) and 2.30 in winter (95% CI 1.45–3.66). Conclusions: IM is associated with MS independently of season, and the association is not stronger for IM during spring, when vitamin D levels reach nadir. The distribution of IM may point towards a correlation with solar radiation or other factors with a similar latitudinal and seasonal variation.

scholarly journals Polymorphisms CYP2R1 rs10766197 and CYP27B1 rs10877012 in Multiple Sclerosis: A Case-Control Study

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
A. Martinez-Hernandez ◽  
E. E. Perez-Guerrero ◽  
M. A. Macias-Islas ◽  
C. A. Nava-Valdivia ◽  
A. Villagomez-Vega ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Disease Progression ◽  
Case Control Study ◽  
Case Control ◽  
Nucleotide Polymorphisms ◽  
Increased Risk ◽  
Vitamin D Levels ◽  
25 Oh Vitamin D ◽  
Control Study

Background. Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease. Low vitamin D levels have been reported to be a risk factor for MS, and genetic variances could be implicated. The aim of this study was to evaluate the association of MS with rs10766197 polymorphism of CYP2R1 gene and rs10877012 polymorphism of CYP27B1 gene. The second aim was to analyse whether these polymorphisms are associated with the severity of the progression of MS. Material and Methods. In a case-control study, we included 116 MS patients and 226 controls, all of whom were Mexican Mestizo. MS was diagnosed by McDonald criteria (2017). A complete neurological evaluation was performed to evaluate the severity of disease progression. Serum 25-hydroxyvitamin D [25(OH) vitamin D] levels were measured by ELISA. Single nucleotide polymorphisms rs10766197 of CYP2R1 gene and rs10877012 SNP of CYP27B1 gene were genotyped by real-time PCR. Results. Serum 25(OH) vitamin D levels were lower in MS patients than in controls ( p = 0.009 ). No differences were observed between serum 25(OH) vitamin D levels of MS patients with severe progression compared to low progression ( p = 0.88 ). A higher frequency of the A allele of CYP2R1 rs10766197 was observed between MS patients and controls ( p = 0.05 ). No differences were observed in the frequency of T allele of CYP27B1 rs10877012 ( p = 0.65 ). In subanalysis, patients with GA + AA genotypes of CYP2R1 rs10766197 had an increased risk of MS compared to controls ( p = 0.03 ). No increased risk was observed in GT + TT genotypes of CYP27B1 rs10877012 ( p = 0.63 ). No differences were observed in allele frequencies of either polymorphism between patients with severe vs. low disease progression. Conclusion. Lower serum 25(OH) vitamin D levels were observed in MS patients than in controls, although these levels were not associated with disease progression. Carriers of GA + AA genotypes of CYP2R1 rs10766197 had an increased risk of MS. None of these polymorphisms was associated with severe progression of MS.

scholarly journals Treatment of Infectious Mononucleosis with High Dose Vitamin D3 in Three Cases

2021 ◽  
Vol 8 (1) ◽  
Author(s):  
Schwalfenberg GK ◽  
Keyword(s):  
Vitamin D ◽  
Vitamin D Receptor ◽  
Infectious Mononucleosis ◽  
Epstein Barr Virus ◽  
Fungal Infections ◽  
High Dose ◽  
Significant Morbidity ◽  
Barr Virus ◽  
Epstein Barr ◽  
High Dose Vitamin

Infectious mononucleosis often results in significant morbidity and disability lasting up to six months. It is known that vitamin D induces cathelicidin production that can rapidly responds to some viral, bacterial and fungal infections. The Epstein Barr virus is able to block the vitamin D receptor thus blocking the ability to fight this infection. This article presents three cases, which responded quickly to loading doses of vitamin D (150,000-200,000 IU) followed by a month of 10,000IU daily.

Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis

2009 ◽  
Vol 15 (4) ◽  
pp. 431-436 ◽  
Author(s):  
TR Nielsen ◽  
K Rostgaard ◽  
J Askling ◽  
R Steffensen ◽  
A Oturai ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Infectious Mononucleosis ◽  
Human Leukocyte ◽  
Epstein Barr Virus Infection ◽  
Leukocyte Antigen ◽  
Barr Virus ◽  
Increased Risk ◽  
History Of ◽  
Epstein Barr ◽  
Barr Virus Infection

Background Both human leukocyte antigen (HLA)-DRB1*15 and Epstein-Barr virus infection presenting as infectious mononucleosis (IM) are recognized as risk factors for multiple sclerosis (MS). However, their combined effect and possible interaction on MS risk is not known. Objective To assess the association between HLA-DRB1*15 and risk of MS in persons with and without IM. Methods We compared the prevalence of DRB1*15 in MS patients with ( n = 76) and without ( n = 1,836) IM with the corresponding distributions in blood donors with ( n = 62) and without ( n = 484) IM histories. This allowed us to estimate the relative risk of MS associated with DRB1*15 in the presence and absence, respectively, of previous IM. We then estimated the interaction between DRB1*15 and IM as the ratio of the two individual odds ratios. Results In IM-naïve individuals, DRB1*15 carried a 2.4-fold (95% confidence interval [CI], 2.0–3.0) increased MS risk. In contrast, among persons with IM history, DRB1*15 was associated with a 7.0-fold (95% CI, 3.3–15.4) increased MS risk. Thus, the MS risk conferred by HLA-DRB1*15 was 2.9 (95% CI, 1.3–6.5)-fold stronger in the presence than in the absence of IM. Combined with previous results, this result indicates that DRB1*15-positive persons with a history of IM may be at a 10.0-fold (95% CI, 6.0–17.9) increased risk of MS compared with persons who are DRB1*15 and IM-naïve. Conclusion DRB1*15 and IM may act in synergy causing MS.

Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients

2016 ◽  
Vol 23 (6) ◽  
pp. 1064-1070 ◽  
Author(s):  
S. Wergeland ◽  
K.-M. Myhr ◽  
K. I. Løken-Amsrud ◽  
A. G. Beiske ◽  
K. S. Bjerve ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Prospective Cohort ◽  
Epstein Barr Virus ◽  
Virus Antibody ◽  
Barr Virus ◽  
Epstein Barr ◽  
Multiple Sclerosis Patients ◽  
Antibody Levels

EBNA-1 reactivity and HLA DRB1*1501 as statistically independent risk factors for multiple sclerosis: a case-control study

2008 ◽  
Vol 14 (8) ◽  
pp. 1120-1122 ◽  
Author(s):  
P Sundström ◽  
L Nyström ◽  
E Jidell ◽  
G Hallmans
Keyword(s):  
Risk Factors ◽  
Multiple Sclerosis ◽  
Case Control Study ◽  
Multivariate Logistic Regression Analysis ◽  
Human Leukocyte ◽  
Case Control ◽  
Nuclear Antigen ◽  
Barr Virus ◽  
Epstein Barr ◽  
Control Study

Objectives and methods The interaction between the two best documented risk factors (human leukocyte antigen [HLA] class II [DRB1*1501 positivity] and Epstein-Barr virus [elevated Epstein-Barr nuclear antigen 1 (EBNA-1) antibody reactivity]) for multiple sclerosis (MS) was studied in a case-control study of biobank samples from 109 MS cases and 212 matched referents. Results Multivariate logistic regression analysis showed that both were statistically significant in both sexes. HLA DRB1*1501-positive referents had higher EBNA-1 reactivity than HLA-negative referents. Less EBNA-1 reactivity was required to increase the MS risk in HLA DRB1*1501-positives than in HLA-negatives. Conclusion We suggest that HLA DRB1*1501-positive individuals have an increased vulnerability to EBV-induced autoimmunity.

Sign in / Sign up

Export Citation Format

Share Document